



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
|-----------------|-------------|----------------------|---------------------|------------------|

09/786,817

06/08/2001

Austin Gerard Smith

06999.0010-0

6701

22852

7590

09/20/2002

FINNEGAN, HENDERSON, FARABOW, GARRETT &
DUNNER LLP
1300 I STREET, NW
WASHINGTON, DC 20006

EXAMINER

WILSON, MICHAEL C

ART UNIT

PAPER NUMBER

1632

DATE MAILED: 09/20/2002

6

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/786,817

Applicant(s)

SMITH ET AL.

Examiner

Michael Wilson

Art Unit

1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 08 June 2001.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 12, 14-21, 25-28, 30-39, 43, 44 and 46-50 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 12, 14-21, 25-28, 30-39, 42, 44 and 46-50 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.
- 4) ☐ Interview Summary (PTO-413) Paper No(s) _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☒ Other: *detailed action*.

Art Unit: 1632

DETAILED ACTION

Claims 1-11, 13, 22-24, 29, 40-42 and 45 have been canceled. Claims 46-50 have been added. Claims 12, 14-21, 25-28, 30-39, 43, 44 and 46-50 are pending and under consideration.

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 12, 14-21, 25-28, 30-39, 43, 44 and 46-50, drawn to a composition comprising a) a compound that promotes propagation of ES cells and b) a compound that inhibits activity of SHP-2, culture medium comprising the composition, and a method of culturing ES cells with said composition, and a method of culturing ES cells with a compound that inhibits activity of SHP-2.

Group II, claims 12, 14-21, 25-28, 30-39, 43, 44 and 46-50, drawn to a composition comprising a) a compound that promotes propagation of ES cells and b) a compound that inhibits the ras/MAPK cascade, culture medium comprising the composition, a method of culturing ES cells with said composition, a method of culturing ES cells with a compound that inhibits the ras/MAPK cascade.

Art Unit: 1632

Group III, claims 12, 14-21, 25-28, 30-39, 43, 44 and 46-50, drawn to a composition comprising a) a compound that promotes propagation of ES cells and b) a compound that inhibits MEK, culture medium comprising the composition, a method of culturing ES cells with said composition, a method of culturing ES cells with a compound that inhibits MEK.

Group IV, claims 12, 14-21, 25-28, 30-39, 43, 44 and 46-50, drawn to a composition comprising a) a compound that promotes propagation of ES cells and b) a compound that inhibits a mitogen activated protein kinase, culture medium comprising the composition, a method of culturing ES cells with said composition, a method of culturing ES cells with a compound that inhibits a mitogen activated protein kinase.

Group V, claims 12, 14-21, 25-28, 30-39, 43, 44 and 46-50, drawn to a composition comprising a) a compound that promotes propagation of ES cells and b) a compound that inhibits cyclin dependent entry into S-phase of non-ES cells, culture medium comprising the composition, a method of culturing ES cells with said composition, a method of culturing ES cells with a compound that inhibits cyclin dependent entry into S-phase of non-ES cells.

The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the claims encompass culturing cells isolated from a blastocyst transfected with a vector encoding a selectable marker operably linked to the oct-4 promoter (US Patent 6,146,888). The vector is a compound that both promotes propagation of the ES cells and inhibits propagation of non-ES cells.

Art Unit: 1632

2. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The following 5 compounds are generic to numerous species:

a compound that inhibits activity of SHP-2,

a compound that inhibits the ras/MAPK cascade,

a compound that inhibits MEK,

a compound that inhibits a mitogen activated protein kinase, and

a compound that inhibits cyclin dependent entry into S-phase of non-ES cells.

If applicants elect group I, applicant is required, in reply to this action, to elect a single species of "a compound that inhibits activity of SHP-2" disclosed in the specification to which the claims shall be restricted if no generic claim is finally held to be allowable.

If applicants elect group II, applicant is required, in reply to this action, to elect a single species of "a compound that inhibits the ras/MAPK cascade" disclosed in the specification to which the claims shall be restricted if no generic claim is finally held to be allowable.

If applicants elect group III, applicant is required, in reply to this action, to elect a single species of "a compound that inhibits MEK" disclosed in the specification to which the claims shall be restricted if no generic claim is finally held to be allowable.

If applicants elect group IV, applicant is required, in reply to this action, to elect a single species of "a compound that inhibits a mitogen activated protein kinase" disclosed in the

Art Unit: 1632

specification to which the claims shall be restricted if no generic claim is finally held to be allowable.

If applicants elect group V, applicant is required, in reply to this action, to elect a single species of "a compound that inhibits cyclin dependent entry into S-phase of non-ES cells" disclosed in the specification to which the claims shall be restricted if no generic claim is finally held to be allowable.

The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable, that all claims are generic or failure to identify the claims readable on the elected species is considered non-responsive.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

It is unclear how PD098059 (claims 46-49) or MAP kinase phosphatase (claim 44) correlates to a compound that inhibits activity of SHP-2, a compound that inhibits the ras/MAPK cascade, a compound that inhibits MEK, a compound that inhibits a mitogen activated protein kinase, and a compound that inhibits cyclin dependent entry into S-phase of non-ES cells. However, claims 12, 14-21, 25-28, 30-39, 43 and 50 are generic to all five genus and all species therein.

Art Unit: 1632

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: .

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Wilson who can normally be reached on Monday through Friday from 9:00 am to 5:30 pm at (703) 305-0120.

Questions of formal matters can be directed to the patent analyst, Dianiece Jacobs, who can normally be reached on Monday through Friday from 9:00 am to 5:30 pm at (703) 305-3388.

Questions of a general nature relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1235.

If attempts to reach the examiner, patent analyst or Group receptionist are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached on (703) 305-4051.

The official fax number for this Group is (703) 308-4242.
Michael C. Wilson



MICHAEL C. WILSON
PATENT EXAMINER